<DOC>
	<DOCNO>NCT02859792</DOCNO>
	<brief_summary>The study conduct two step : 1 . Determination Minimal Effective Dose ( MED ) among four dos panel 2 . Estimation probability response associate MED . Each step main objective : Step 1 Objective : To determine daily dose Riluzole improve spasticity patient chronic SCI Step 2 Objective : To demonstrate , phase 2b trial , efficacy Riluzole improve spasticity v placebo , patient chronic SCI .</brief_summary>
	<brief_title>Riluzole Treatment Spasticity Traumatic Chronic Spinal Cord Injury Condition</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>1 . Chronic traumatic SCI define : . At least 12month history : i. C4T12 traumatic SCI ii . Complete incomplete ( AIS A , B , C , D ) iii . With Spasticity ( 5 &gt; MAS &gt; 1 least adductor muscle and/or triceps surae muscle NRS ≥ 4 ) 2 . Male Female 3 . Aged 18 65 year time screen 4 . Judged site investigator able comply evaluation baseline throughout study 5 . Last injection BTXA striate muscle 3 month ago patient must return level spasticity BTXA injection 6 . Last intrathecal ( IT ) injection baclofen per o administration myorelaxant 14 day ago ( Step 1 ) 7 . The dose myorelaxant Baclofen stable ≥ 30 day prior screen keep stable daily dose end protocol ( Step 2 ) . 8 . Stable chronic medication ≥ 30 day prior screen , include analgesic 9 . Stable rehabilitation ( method frequency ) ≥ 15 day prior screen 10 . Written inform consent provide subject 1 . Spinal cord injury le 12 month , 2 . Associated Brain lesion might cause spasticity , 3 . MAS≤1 =5 least adductor muscle and/or triceps surae muscle NRS &lt; 4 4 . Presence urinary infection , fever , pressure ulcer spasticityaggravating factor . 5 . Presence significant neurological mental disorder illness , would preclude accurate evaluation , 6 . Recent history ( less 1 year ) chemical substance dependency significant psychosocial disturbance , 7 . Insufficient fluency local language complete neuropsychological , global spasticity assessment 8 . Active liver disease clinical jaundice 9 . Active malignancy history invasive malignancy within last five year 10 . Neutropenia , liver enzymes ( ALT/SGPT AST/SGOT ) 2 time upper limit normal ( ULN ) screen visit , baseline elevation several liver function test ( especially elevate bilirubin ) . 11 . AIDS AIDSrelated complex , 12 . The systolic blood pressure measurement &gt; 190 &lt; 85 mm Hg and/or diastolic blood pressure measurement &gt; 105 &lt; 50 mm Hg screening . 13 . The ECG abnormal screen judge clinically significant site investigator . Particular attention give sign suggest conduction disorder . 14 . Treatment investigational drug device within 60 day screen 15 . Any myorelaxant medication include IT baclofen , take subject last 14 day prior screen ( step 1 ) 16 . Not stable IT baclofen per o myorelaxant medication least 30 day prior screen ( step 2 ) 17 . Not stable chronic medication ≥ 30 day prior screen , include analgesic 18 . Injection BTXA striate muscle le 3 month ago 19 . Subject currently use , continue use next 14 day follow medication classify Inhibitors CYP 1A2 ( e.g . diclofenac , diazepam , nicergoline , clomipramine , imipramine , fluvoxamine , phenacetin , theophylline , amitriptyline quinolones ) Inducers CYP 1A2 ( e.g . rifampicin omeprazole ) 20 . Ongoing pregnancy lactation . Women childbearing potential use form efficacious contraception . 21 . Known hypersensitivity Riluzole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>